UroGen Pharma Ltd. (NASDAQ:URGN) Holdings Raised by RTW Investments LP

RTW Investments LP raised its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 6.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,787,347 shares of the company's stock after purchasing an additional 230,000 shares during the period. RTW Investments LP owned 16.15% of UroGen Pharma worth $48,099,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Coastal Bridge Advisors LLC raised its holdings in shares of UroGen Pharma by 4.1% during the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company's stock valued at $646,000 after buying an additional 1,500 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in UroGen Pharma by 3.4% during the 2nd quarter. Rice Hall James & Associates LLC now owns 72,787 shares of the company's stock valued at $1,221,000 after acquiring an additional 2,381 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after acquiring an additional 3,856 shares in the last quarter. ARK Investment Management LLC boosted its position in UroGen Pharma by 3.7% during the 2nd quarter. ARK Investment Management LLC now owns 151,781 shares of the company's stock worth $2,547,000 after acquiring an additional 5,452 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after purchasing an additional 5,890 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

URGN has been the topic of a number of recent analyst reports. Guggenheim started coverage on shares of UroGen Pharma in a research note on Thursday, August 22nd. They set a "buy" rating and a $40.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, Oppenheimer reiterated an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, UroGen Pharma currently has an average rating of "Buy" and an average target price of $48.38.

UroGen Pharma Price Performance

UroGen Pharma stock traded down $0.25 during midday trading on Thursday, hitting $12.21. The company's stock had a trading volume of 479,906 shares, compared to its average volume of 496,578. UroGen Pharma Ltd. has a 12 month low of $10.60 and a 12 month high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $286.32 million, a PE ratio of -3.88 and a beta of 1.06. The stock's 50-day moving average price is $12.29 and its 200-day moving average price is $13.96.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same period in the prior year, the firm earned ($0.68) EPS. Analysts anticipate that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.